A downtrend has been apparent in Inozyme Pharma, Inc. (INZY) lately with too much selling pressure. The stock has declined 30% over the past four weeks. However, given the fact that it is now in ...
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Inozyme Pharma, Inc. (NASDAQ:INZY) stands against the other biotech ...
Investors are always looking for stocks that are poised to beat at earnings season and Inozyme Pharma, Inc. INZY, may be one such company. The firm has earnings coming up pretty soon, and events are ...
Shares of Boston-based Inozyme Pharma (INZY) have fallen by over 80% since IPO was priced at $16 in July of 2020. During the past 12 months, they've posted a still dismal -58% performance. With ...
Inozyme is a rare disease therapy developer with a lead asset, INZ-701, targeting ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 has shown safety and tolerability in trials and has the potential to ...
Short interest in Inozyme Pharma Inc (NASDAQ:INZY) decreased during the last reporting period, falling from 3.84M to 3.68M. This put 6.16% of the company's publicly available shares short. Short ...
Inozyme Pharma Inc. Annual cash flow by MarketWatch. View INZY net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results